Replies to post #15165 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

How about we get a reality check here?

55

So, $2.8M cash on hand to run the paperwork for the Ifenprodil CC and Tumor Trials AND preclinical DMT work with Charles River. Updating patent applications, ect.

Probably have plenty $ left for initial NASDAQ research/filings/prospectus.

I truly question whether or not you're just pulling everyone's leg with many/most of your posts.

Let's have another look (for the Umpteenth Thousanth Cabillion time) at the companies own example of cost of clinical trials:



Do you SEE where the arrow points in between Phase 1 and Phase 2?

If so, what the company has communicated to the public is the average cost of a Phase 2 clinical trial is $35 Million US$

Given that, HOW IS IT the company also told the public it could run a Phase 2 clinical trial for around $5 Million CAD?

I'll tell you how...They Were F**KING LYING!

The above chart represents a Real World Placebo Controlled Phase 2 clinical trial powered for statistical significance.

That IS NOT the same as the PUSSYFOOTING around studies thus far pumped out by Algernon Pharmaceuticals.


It's my assumption the standalone Chronic Cough clinical trial will cost somewhere between $10 Million and $20 Million USD. That's saying they're actually planning to conduct a trial that gets results within a year or so like the "PURE COMPARATOR" Bellus Health. Otherwise, whatever they do on the cheap will be at a snails pace just like AU/NZ.

Unfortunately, the latter is more likely.

Past behavior is the best predictor of future behavior, and the same is true of success. People who experience small victories build the confidence – and the momentum – to keep going.Apr 23, 2018

8 Traits That Are Scientifically Proven To Predict Future Success https://www.forbes.com

Christopher Moreau spent 10 years at a failed company before he landed the job at Algernon Pharmaceuticals. The new Chairman of the Board (Harry Bloomfield) worked at the same company. So did Moreau's brother.

But I digress.

The only play I see here before 2024 is - if they can get any traction with a partnership after the DMT Phase I clinical trial. The cancer angle seems like a millennial away from bearing any fruit. As 99.99% of all cancer angles fail.

Furthermore, an uplisting to NASDAQ IS NOT a catalyst.

It's a whitewash of past pathetic practices by Team Cobra. You're still left with the same management team in place - with the same over inflated egos and conflicts of interest running around the cubicle rented out by former CFO, Michael SADhra - SAD.

If there's ever a positive surprise coming from management I'll be shocked into submission.



As to Doc Williams whereabouts...who knows?

What I do know is the drug he co-invented @ DiaMedica Therapeutics appears to be in position for some massive gains:

DiaMedica has one leading drug candidate, currently undergoing two clinical trials. In the first, DM199 is undergoing a Phase 2/3 study in the treatment of AIS, the REMEDY study. The drug is used to promote microcirculation when administered up to 24 hours post onset of stroke symptoms. This is a longer window than with existing stroke therapies. The REMEDY study was initiated in the summer of this year, and has 350 patients. The FDA has granted Fast Track designation to DM199 for this indication.

In line with these comments, Nowak gives DMAC a Buy rating along with an $18 price target that indicates potential for 322% upside in the coming year. (To watch Nowak’s track record, click here.)

All in all, DiaMedica has a Strong Buy consensus rating based on 4 unanimously positive analyst reviews. This stock is selling for $4.23 per share, and its $18.50 average price target implies it has room for 334% growth over the next 12 months.

The takeaway from this is the speed with which they were able to get significant data, and DM199 appears to be positioning itself for massive gains in the Ischemic Stroke arena.

Does Ischemic Stroke sound familiar? Yeah, it was Doc Williams latest brainstorm (AP188 - DMT for Stroke and constraint-induced movement therapy (CIMT) for the treatment of upper-limb dysfunction in stroke patients) before he stormed out of Algernon's door. He returns to a company with daily historical low stock prices and no end in sight to the seemingly useless AU/NZ "study".

Word to "Management" - don't ever try pulling those BULLSHIT @SS NON Statistically Significant Studies over our eyes again.

Do you really think that type of BS would have ever been pulled on NASDAQ?

My guess is management believes OTC is tryuly stupid because they've gotten away with so much crap from one year to the next.

In that vein I couldn't agree more.

OTC shareholders are weak - Silence Of The Lambs.

However, my best guess is management won't pull that SH!T again since some of us will air that sh!t out in public 24/7/365.

Try Pulling The Wool Over The Sheeples Eyes Again



Go ahead "management", I DARE YA!

T G I F

peace,

M$